NCT02228850View on ClinicalTrials.gov

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
DRUG

Alprostadil

OTHER

Placebo

Trial Locations (4)

15261

Scleroderma Research Center - University of Pittsburgh School of Medicine, Pittsburgh

44195

Cleveland Clinic, Cleveland

48109

University of Michigan Scleroderma Program - Division of Rheumatology/Dept. of Internal Medicine, Ann Arbor

92024

Diagnamics, Inc., Encinitas

All Listed Sponsors
lead

NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

INDUSTRY

NCT02228850 - Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis | Biotech Hunter | Biotech Hunter